Quantcast

FDA accepts Viela Bio application

The Food and Drug Administration has accepted for review a biologics license application from Gaithersburg-based Viela Bio Inc. for a drug in development. The application is for inebilizumab, a drug for the treatment of patients with neuromyelitis optica spectrum disorder, a  rare disease that can lead to severe disability, including blindness and paralysis. Dr. Jorn Drappa, chief ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.

Leave a Reply

Your email address will not be published. Required fields are marked *

*